(Q35650640)

9 August 2017

1 reference

title

Latent tuberculosis infection--Revisiting and revising concepts (English)

1 reference

9 August 2017

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26038289%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Edward Jones Lopez

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26038289%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Padmini Salgame

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26038289%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Carolina Geadas

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26038289%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Jerrold J Ellner

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26038289%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

15 May 2015

1 reference

9 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26038289%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26038289%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26038289%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

373-384

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26038289%20AND%20SRC:MED&resulttype=core&format=json

LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Gamma interferon release assays for detection of Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Reproducibility of interferon gamma (IFN-γ) release Assays. A systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Occupational Screening for Tuberculosis. A Testing Time for Interferon-γ Release Assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The infectiousness of tuberculosis patients coinfected with HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Importance of cough and M. tuberculosis strain type as risks for increased transmission within households.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Cough aerosols of Mycobacterium tuberculosis predict new infection: a household contact study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Tuberculin skin test negativity is under tight genetic control of chromosomal region 11p14-15 in settings with different tuberculosis endemicities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Mycobacterium tuberculosis Beijing strains favor transmission but not drug resistance in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The time-table of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The long-term dynamics of tuberculosis and other diseases with long serial intervals: implications of and for changing reproduction numbers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The prognosis of a positive tuberculin reaction in childhood and adolescence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Contact investigation for tuberculosis: a systematic review and meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Development of Tuberculosis in Infected Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Epidemiology of tuberculosis in Galicia, Spain, 16 years after the launch of the Galician tuberculosis programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The epidemiology of tuberculosis infection in a closed environment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Incident tuberculosis among recent US immigrants and exogenous reinfection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Incidence of tuberculosis in HIV-infected patients in Spain: the impact of treatment for LTBI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Priorities for the Treatment of Latent Tuberculosis Infection in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Pathogenesis of the Sporadic Case of Tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Mycobacterium tuberculosis-specific cellular immune profiles suggest bacillary persistence decades after spontaneous cure in untreated tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

A polymorphism in human TLR2 is associated with increased susceptibility to tuberculous meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Innate Immunity to TB: A Druggable Balancing Act

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Does vitamin D deficiency account for ethnic differences in tuberculosis seasonality in the UK?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Epidemiologic inference from the distribution of tuberculosis cases in households in Lima, Peru

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Secondary attack rate of tuberculosis in urban households in Kampala, Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Immunoregulation in TB: observations and implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The elusive "gold" standard for detecting Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The role of the interferon gamma release assay in assessing recent tuberculosis transmission in a hospital incident

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Short-term reproducibility of a commercial interferon gamma release assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Within-subject variability of Mycobacterium tuberculosis-specific gamma interferon responses in German health care workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Unusual interferon gamma measurements with QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube tests.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Repeat IGRA testing in Canadian health workers: conversions or unexplained variability?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Challenges with QuantiFERON-TB Gold assay for large-scale, routine screening of U.S. healthcare workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Longitudinal analysis of QuantiFERON-TB Gold In-Tube in children with adult household tuberculosis contact in South Africa: a prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

7 January 2021

The tuberculin skin test

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Instability of tuberculin and Candida skin test reactivity in HIV-infected Ugandans. The Uganda-Case Western Reserve University Research Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Discordance of tuberculin skin test and interferon gamma release assay in recently exposed household contacts of pulmonary TB cases in Brazil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Time interval to conversion of interferon-gamma release assay after exposure to tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Tuberculin skin test and interferon-γ release assay show better correlation after the tuberculin ‘window period’ in tuberculosis contacts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Highly discordant T cell responses in individuals with recent exposure to household tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Comparison of two interferon gamma release assays in the diagnosis of Mycobacterium tuberculosis infection and disease in The Gambia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Quantitative T cell assay reflects infectious load of Mycobacterium tuberculosis in an endemic case contact model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The tuberculin skin test versus QuantiFERON TB Gold® in predicting tuberculosis disease in an adolescent cohort study in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Decay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Evaluation of quantitative IFN-gamma response for risk stratification of active tuberculosis suspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The non-human primate model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Reactivation of latent tuberculosis in rhesus macaques by coinfection with simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Tuberculin skin test reversion following isoniazid preventive therapy reflects diversity of immune response to primary Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

A 19-Year Follow-up of Tuberculin Reactors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The effect of previous tuberculin skin test on the follow-up examination of whole-blood interferon-gamma assay in the screening for latent tuberculosis infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The tuberculin skin test increases the responses measured by T cell interferon-gamma release assays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-gamma assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Evidence for boosting Mycobacterium tuberculosis-specific IFN-gamma responses at 6 weeks following tuberculin skin testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Human gene expression profiles of susceptibility and resistance in tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Common patterns and disease-related signatures in tuberculosis and sarcoidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Transcriptional responses of host peripheral blood cells to tuberculosis infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Whole genome sequencing of Mycobacterium tuberculosis reveals slow growth and low mutation rates during latent infections in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Altered T cell memory and effector cell development in chronic lymphatic filarial infection that is independent of persistent parasite antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Altered proportions of naïve, central memory and terminally differentiated central memory subsets among CD4+ and CD8 + T cells expressing CD26 in patients with type 1 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Antigen burden is major determinant of human immunodeficiency virus-specific CD8+ T cell maturation state: potential implications for therapeutic immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Distinct effector memory CD4+ T cell signatures in latent Mycobacterium tuberculosis infection, BCG vaccination and clinically resolved tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+CCR6+ Th1 subset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Resident Th1-like effector memory cells in pulmonary recall responses to Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Diagnostic accuracy and clinical role of rapid C-reactive protein testing in HIV-infected individuals with presumed tuberculosis in South Africa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Correlates for disease progression and prognosis during concurrent HIV/TB infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Elevated levels of circulating adhesion molecules in patients with active pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

A metabolic biosignature of early response to anti-tuberculosis treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Dynamic antibody responses to the Mycobacterium tuberculosis proteome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Double-phase 18F-FDG PET-CT for determination of pulmonary tuberculoma activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Usefulness of 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Dual-time point positron emission tomography findings of benign mediastinal lymph nodes in a tuberculosis-endemic region.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Increased cellular activity in thoracic lymph nodes in early human latent tuberculosis infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

A small RNA encoded in the Rv2660c locus of Mycobacterium tuberculosis is induced during starvation and infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003

The ongoing challenge of latent tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2015.04.003